News
EMA starts twin reviews of AZ, Daiichi’s Dato-DXd
The clock has started ticking in the EU on two marketing applications for AstraZeneca and Daiichi Sankyo’s TROP2-targeting antibody-drug conjugate datopotamab deruxtecan i
